Distinguished Research Fellow, AbbVie,
Dale Kempf, has more than 25 years of pharmaceutical R&D experience, mostly in antiviral research. He is a co-inventor of Norvir® and Kaletra®, HIV protease inhibitors that are widely used for the therapy of HIV infection, and has co-directed Abbott’s collaboration hepatitis C virus discovery effort, resulting in several compounds presently in clinical development.
Dr. Kempf is co-chair of the Bill and Melinda Gates Foundation CEO Round Table Translational Research Working Group, and serves on the Steering Committee for the HCV Drug Development Advisory Group through the Forum for Collaborative HIV Research.
He also serves on the Organizing Committee for the International Workshop on Hepatitis C – Resistance and New Compounds. Within Abbott, Dr. Kempf is a member of the Medicinal Chemistry Leadership Team as well as the Executive Council for Neglected Diseases, a cross-divisional initiative working to increase Abbott engagement in underserved disease areas.
Dr. Kempf has published widely in areas of medicinal chemistry, pharmacology and drug resistance, with more than 120 scientific publications and 50 U.S. patents to his credit. He has received a number of awards and recognitions, including Abbott Outstanding Researcher, the Heroes of Chemistry Award from the American Chemical Society, the Discoverers Award from the Pharmaceutical Research and Manufacturers of America, and National Inventor of the Year from the Intellectual Property Owners Association.